Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)

Background: The purpose of this study is to identify and characterize ocular adverse events (AEs) that are significantly associated with anti-VEGF drugs for treatment of neovascular age-related macular degeneration and compare the differences between each drug, and provide clinical reference.Methods...

Full description

Bibliographic Details
Main Authors: Pan Ma, Xinmei Pan, Ruixiang Liu, Ya Qu, Linli Xie, Jiangchuan Xie, Liya Cao, Yongchuan Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Pharmacology
Subjects:
adverse events
pharmacovigilance
ranibizumab
aflibercept
brolucizumab
safety signals
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1017889/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.1017889/full

Similar Items